Helping thousands of children on an annual basis through the effective detection and distribution of therapies for leukemia.

The Center for Research Promotion in Pediatrics based in Essen, Germany was founded in 2011 out of the adversities of everyday pediatric oncology. The center is a highly specialized service provider in the field of pediatrics and adolescent medicine and works particularly in the field of pediatric oncology and hematology.

Within the center is a research institute and reference laboratory AML-BFM. The objective of the AML laboratory is towards the development of an immunotherapy for acute myeloid leukemias (AMLs). Acute myeloid leukemia in children and adolescents is a very rare disease, but one that is fatal if left untreated. It can affect any child. In Germany, around 130 children develop acute myeloid leukemia (AML) each year. The only way to cure these children is with intensive chemotherapy. Click here to read more.

The task of the AML-BFM reference laboratory in Essen and the goal of pediatric AML diagnostics is to identify a leukemia-specific biomarker that can measure the risk of the disease and the success of the therapy protocols during and after clinical intervention. After the initial diagnostics, which detect AML-specific somatic mutations at the genomic level and/or corresponding fusion transcripts via their expression using specific mRNA, a leukemia clone-specific signature can be used for therapy.

Timely diagnosis and communication of the results can be used by the sending centers to control therapy and, if necessary, to prevent a recurrence of the disease. The Siebel CRM application has helped tremendously in organizing the data, increasing stability and quality of patients outcome control. The results of the research have been extremely successful, helping thousands of children on an annual basis.